CEBPA-DT

Across TCGA pan-cancer cohorts, CEBPA-DT RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of CEBPA-DT’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where CEBPA-DT RNA is repressed in tumor relative to normal tissue. In most cancer types CEBPA-DT is over-expressed in tumor, although a few such as THCA and LUAD show the opposite, repressed pattern.

THCA, LUAD, and LIHC are the cancer types where CEBPA-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CEBPA-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−2.224	<.001	10	view →
LUAD	Female	III,IV	−1.462	<.001	9	view →
LIHC	Male	All	+1.244	<.001	8	view →
UCEC	All	All	−2.189	<.001	6	view →
BRCA	All	II,III,IV	−1.158	<.001	6	view →
KIRP	Male	All	+0.814	<.001	6	view →
KICH	All	III,IV	−0.717	.001	5	view →
HNSC	All	III,IV	−0.379	.012	4	view →
BLCA	All	All	+0.647	.025	3	view →
PRAD	All	All	+0.443	.007	2	view →
READ	Female	All	+0.775	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

CEBPA-DT–THCA

Open the THCA breakdown →